ArticleCancers2022

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer.

Julie E Bauman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.